Modulation of the endocannabinoid system through diet, physical activity and microbiome in the new era of multiple sclerosis.
Maccarrone Giuseppe G, Montaguti Luca L, Bruno Antonio A, Borrelli Angela A et al.
Multiple sclerosis (MS) is a chronic immune-mediated disorder characterized by neuroinflammation, inflammatory synaptopathy, and progressive neurodegeneration. Increasing evidence identifies the endocannabinoid system (ECS) as a regulator of synaptic transmission, neuroinflammatory tone, and neuroplasticity; however, its translational relevance in people with MS remains incompletely established. Cannabinoid-based compounds have their most established clinical role in symptomatic treatment, particularly for residual symptoms within the spasticity-plus syndrome, whereas effects on excitotoxicity, microglial activation, and neuroinflammation are supported mainly by mechanistic and preclinical evidence. Lifestyle-related factors, including physical activity, diet, and gut microbiome composition, have been associated with ECS-related signaling changes in healthy individuals and experimental models, but direct evidence of ECS-mediated effects in MS remains limited. Physical activity can increase circulating levels of the endocannabinoid anandamide in healthy individuals, while dietary components may influence ECS-related pathways through polyunsaturated fatty acids and phytochemicals; however, direct ECS-mediated clinical effects of either intervention in MS have not been demonstrated. Experimental evidence also supports bidirectional interactions between the gut microbiome and the ECS, although their clinical relevance in MS remains uncertain. Overall, these findings support a biologically plausible, hypothesis-generating framework linking lifestyle factors and ECS-related pathways alongside disease modifying treatments, without demonstrating causal mediation or disease-modifying efficacy. This review integrates preclinical and clinical evidence to distinguish established symptomatic effects from biological plausibility and indirect associations, and highlights priorities for prospective validation and personalized multimodal MS management.